| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
17,672 |
16,818 |
$1.48M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
7,342 |
6,816 |
$728K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
2,765 |
2,660 |
$187K |
| 85027 |
|
5,644 |
5,021 |
$52K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
604 |
576 |
$28K |
| 80053 |
Comprehensive metabolic panel |
2,190 |
1,974 |
$26K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
215 |
190 |
$25K |
| G0378 |
Hospital observation service, per hour |
249 |
132 |
$23K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
991 |
922 |
$19K |
| 83735 |
|
139 |
98 |
$9K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
76 |
74 |
$6K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
117 |
94 |
$5K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
344 |
337 |
$5K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
131 |
122 |
$3K |
| 70450 |
Computed tomography, head or brain; without contrast material |
78 |
70 |
$3K |
| 87430 |
|
375 |
354 |
$3K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
94 |
89 |
$2K |
| 84484 |
|
149 |
103 |
$2K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
42 |
42 |
$1K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
42 |
42 |
$1K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
174 |
151 |
$1K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
16 |
16 |
$1K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
99 |
95 |
$1K |
| 81025 |
|
195 |
189 |
$1K |
| 87428 |
|
55 |
46 |
$1K |
| 87081 |
|
172 |
170 |
$959.14 |
| 71046 |
Radiologic examination, chest; 2 views |
116 |
111 |
$876.71 |
| 83880 |
|
54 |
49 |
$834.35 |
| 82553 |
|
72 |
61 |
$804.35 |
| 71045 |
Radiologic examination, chest; single view |
199 |
170 |
$789.17 |
| 83690 |
|
124 |
112 |
$702.05 |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
26 |
26 |
$666.33 |
| 96361 |
Intravenous infusion, hydration; each additional hour |
58 |
56 |
$643.82 |
| 36415 |
Collection of venous blood by venipuncture |
1,131 |
995 |
$540.29 |
| 81001 |
|
220 |
208 |
$529.20 |
| 82550 |
|
74 |
63 |
$454.44 |
| 84703 |
|
66 |
61 |
$427.06 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
49 |
48 |
$398.16 |
| 87807 |
|
32 |
32 |
$317.98 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
44 |
32 |
$250.80 |
| 85379 |
|
34 |
32 |
$248.75 |
| 74018 |
|
35 |
33 |
$243.18 |
| 85610 |
|
65 |
56 |
$209.50 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
100 |
84 |
$187.72 |
| 80306 |
|
14 |
13 |
$176.69 |
| 84443 |
Thyroid stimulating hormone (TSH) |
14 |
12 |
$161.45 |
| 81003 |
|
255 |
238 |
$158.48 |
| 85730 |
|
48 |
43 |
$155.98 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
160 |
138 |
$125.22 |
| 86850 |
|
14 |
14 |
$86.66 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
31 |
29 |
$69.74 |
| 86901 |
|
14 |
14 |
$67.18 |
| 86900 |
|
14 |
14 |
$52.75 |
| 87210 |
|
12 |
12 |
$44.74 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
39 |
31 |
$36.95 |
| J2550 |
Injection, promethazine hcl, up to 50 mg |
16 |
14 |
$28.39 |
| J2060 |
Injection, lorazepam, 2 mg |
19 |
15 |
$18.45 |
| J7050 |
Infusion, normal saline solution, 250 cc |
73 |
58 |
$6.67 |
| A9270 |
Non-covered item or service |
118 |
21 |
$0.00 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
71 |
66 |
$0.00 |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
15 |
15 |
$0.00 |